Literature DB >> 32081714

Risk factors and oncological outcome for intravesical recurrence in organ-confined upper urinary tract urothelial carcinoma patients after radical nephroureterectomy: A propensity score-matched case control study.

Yunzhong Jiang1, Zichuan Yao2, Xianqing Zhu3, Bin Wu4, Song Bai5.   

Abstract

PURPOSE: Radical nephroureterectomy (RNU) is the primary treatment strategy for upper urinary tract urothelial carcinoma (UTUC); however, the prognosis is poor and recurrences are common. The risk factors for intravesical recurrence (IVR) remain inconsistent and unclear. Thus, we have identified the risk factors for IVR in patients with organ-confined UTUC.
METHODS: We retrospectively studied 229 patients with UTUC who underwent RNU combined with bladder cuff resection at our center between 1 January 2010 and 31 December 2015. After propensity score-matching, 204 patients were included in our study. Patient demographics, co-morbidities, and peri-operative data were recorded. Univariate and multivariate Cox proportional hazard regression were used to estimate the hazard ratio and 95% confidence intervals. Overall (OS) and cancer-specific survival (CSS) were measured using the Kaplan-Meier curve with a log-rank test. A p-value <0.05 was considered statistically significant.
RESULTS: Of the 229 patients, 42 (18.3%) had IVR after 40 months (range, 24-56 months) follow-up. In the matched group, the independent risk factors for IVR were tumor diameter (HR = 2.690, p = 0.038) and tumor stage (T3 vs. T1, HR = 3.363, p = 0.019; T2 vs. T1, HR = 2.835, p = 0.022). OS and CSS were poor in patients with IVR than patients without IVR (p < 0.0001).
CONCLUSIONS: In this propensity score-matched case-control study, tumor diameter and tumor stage were shown to be independent risk factors for IVR in patients with organ-confined UTUC. Moreover, patients with IVR had poor prognosis than patients without IVR. Thus, more active postoperative surveillance and treatment strategies should be adopted for these patients, which may help improve treatment outcomes.
Copyright © 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Intravesical recurrence (IVR); Organ-confined; Radical nephroureterectomy (RNU); Upper urinary tract urothelial carcinoma (UTUC)

Mesh:

Year:  2020        PMID: 32081714     DOI: 10.1016/j.ijsu.2020.02.015

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  4 in total

1.  Impact of previous, simultaneous or intravesical recurrence bladder cancer on prognosis of upper tract urothelial carcinoma after nephroureterectomy: a large population-based study.

Authors:  Shuxiong Zeng; Yidie Ying; Xiaowen Yu; Linhui Wang; Zhensheng Zhang; Chuanliang Xu
Journal:  Transl Androl Urol       Date:  2021-12

2.  Predictive Value of Preoperative Positive Urine Cytology for Development of Bladder Cancer After Nephroureterectomy in Patients With Upper Urinary Tract Urothelial Carcinoma: A Prognostic Nomogram Based on a Retrospective Multicenter Cohort Study and Systematic Meta-Analysis.

Authors:  Bo Fan; Yuanbin Huang; Shuang Wen; Qiliang Teng; Xinrui Yang; Man Sun; Tingyu Chen; Yan Huang; Yumei Wang; Zhiyu Liu
Journal:  Front Oncol       Date:  2021-10-01       Impact factor: 6.244

3.  The Prognostic Impact of Tumor Location in pT3N0M0 Upper Urinary Tract Urothelial Carcinoma: A Retrospective Cohort Study.

Authors:  Tzu Shuang Chen; Yen Ta Chen; Hung Jen Wang; Po Hui Chiang; Wen Chou Yang; Wei Ching Lee; Yao Chi Chuang; Yuan Tso Cheng; Chih Hsiung Kang; Wei Chia Lee; Chien Hsu Chen; Yuan Chi Shen; Yi Yang Liu; Hui Ying Liu; Yin Lun Chang; Yu Li Su; Chun Chieh Huang; Hao Lun Luo
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

4.  Risk Factors for Unfavorable Pathological Types of Intravesical Recurrence in Patients With Upper Urinary Tract Urothelial Carcinoma Following Radical Nephroureterectomy.

Authors:  Jun Zhu; Xiaoqing Zhang; Wei Yu; Xuesong Li; Zhisong He; Liqun Zhou; Zhongyuan Zhang; Gengyan Xiong
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.